| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | Pazopanib | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |